EPCAM and neoplasm: Although a variety of biomarkers such as CD44, CD133, CD47, cMET, EGFR, and immune checkpoint inhibitors are heterogeneously expressed on CTCs derived from different tumor entities, the most common techniques for the ex vivo separation of CTCs from peripheral blood are based on the capturing of cells using antibodies directed against cell surface expressed EpCAM (CD326) (22–26).